SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
18638004
Source:
http://linkedlifedata.com/resource/pubmed/id/18638004
Search
Subject
(
68
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0036043
,
umls-concept:C0087111
,
umls-concept:C0242350
,
umls-concept:C0442027
,
umls-concept:C1318700
,
umls-concept:C2353244
pubmed:issue
11
pubmed:dateCreated
2008-11-13
pubmed:abstractText
Mirodenafil is a newly developed oral phosphodiesterase type 5 inhibitor, currently under investigation as a treatment for erectile dysfunction (ED).
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/101230693
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase 5 Inhibitors
,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors
,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones
,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides
,
http://linkedlifedata.com/resource/pubmed/chemical/mirodenafil
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1743-6109
pubmed:author
pubmed-author:AhnTai YTY
,
pubmed-author:ChoiHyung KHK
,
pubmed-author:ChungWoo-SikWS
,
pubmed-author:HUSSGG
,
pubmed-author:JungHyung-GiHG
,
pubmed-author:KimSae CSC
,
pubmed-author:KimSae WSW
,
pubmed-author:LeeSung WSW
,
pubmed-author:MinKweon SKS
,
pubmed-author:MoonKi HKH
,
pubmed-author:PaickJae-SeungJS
,
pubmed-author:ParkJong KJK
,
pubmed-author:ParkKwangsungK
,
pubmed-author:ParkNam CNC
,
pubmed-author:SuhJun-KyuJK
,
pubmed-author:YangDae YDY
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2672-80
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18638004-Administration, Oral
,
pubmed-meshheading:18638004-Adult
,
pubmed-meshheading:18638004-Aged
,
pubmed-meshheading:18638004-Dose-Response Relationship, Drug
,
pubmed-meshheading:18638004-Double-Blind Method
,
pubmed-meshheading:18638004-Erectile Dysfunction
,
pubmed-meshheading:18638004-Humans
,
pubmed-meshheading:18638004-Korea
,
pubmed-meshheading:18638004-Male
,
pubmed-meshheading:18638004-Middle Aged
,
pubmed-meshheading:18638004-Patient Satisfaction
,
pubmed-meshheading:18638004-Phosphodiesterase 5 Inhibitors
,
pubmed-meshheading:18638004-Phosphodiesterase Inhibitors
,
pubmed-meshheading:18638004-Pyrimidinones
,
pubmed-meshheading:18638004-Sulfonamides
,
pubmed-meshheading:18638004-Treatment Outcome
,
pubmed-meshheading:18638004-Young Adult
pubmed:year
2008
pubmed:articleTitle
Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.
pubmed:affiliation
Department of Urology, Seoul National University Hospital, Seoul, Korea. jspaick@snu.ac.kr
pubmed:publicationType
Journal Article
,
Comparative Study
,
Randomized Controlled Trial
,
Research Support, Non-U.S. Gov't
,
Multicenter Study